Letters |

PEPFAR and Adult Mortality—Reply

Eran Bendavid, MD, MS; Charles B. Holmes, MD, MPH; Grant Miller, PhD, MPP
JAMA. 2012;308(10):972-973. doi:10.1001/jama.2012.9249.
Text Size: A A A
Published online


In Reply: Dr Shelton is concerned about the possibility of overestimating the association of PEPFAR with mortality in the 2 most populous countries, Ethiopia and Nigeria. This concern is only relevant to the estimation of the number of deaths averted and not to the main estimation of the overall mortality risk reduction. Shelton's point about the expectation of smaller effect on all-cause adult mortality from expansion of antiretroviral therapy in places where HIV prevalence is low is well taken. However, our country-specific estimates were based on the difference in the predicted mortality rates with and without PEPFAR for each country. As a result, the estimates of number of deaths averted in each of the 9 focus countries ranged from 2.4% to 17.4%. Our estimates involved substantial uncertainty (95% CI, 443 300-1 808 500 deaths averted), and our point estimate (740 800) should be viewed in that context.

Figures in this Article


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Figure. Age-Adjusted Mortality by the President's Malaria Initiative (PMI) Partner Country Group
Graphic Jump Location

Differential mortality trends are not obvious between PMI partner and non–PMI partner countries while PMI was implemented. A narrow-bandwidth (0.6) lowess curve was used to fit the trend. Lowess (locally weighted scatterplot smoothing) is a nonparametric method of fitting a curve using local regressions for each point. Error bars indicate 95% confidence intervals.



September 12, 2012
James D. Shelton, MD, MPH
JAMA. 2012;308(10):972-973. doi:10.1001/jama.2012.9243.
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.